The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.

Qing, Yong; Yamazoe, Mitsuyoshi; Hirota, Kouji; Dejsuphong, Donniphat; Sakai, Wataru; Yamamoto, Kimiyon; Bishop, Douglas K; Wu, Xiaohua; Takeda, Shunichi

Qing, Yong ...[et al]. The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.. PLoS genetics 2011, 7(7): e1002148.

© 2011 Qing et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination

Yong Qing1*, Mitsuysahi Yamazoe1*, Kouji Hirota1, Donniphat Dejsuphong1, Wataru Sakai1, Kimygo N. Yamamoto1, Douglas K. Bishop2, Xiaohua Wu3, Shunichi Takeda1*

1 Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2 Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, United States of America, 3 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medicinal School, Sichuan University, Chengdu, China

Abstract

RAD51 recombinase polymerizes at the site of double-strand breaks (DSBs) where it performs DSB repair. The loss of RAD51 causes extensive chromosomal breaks, leading to apoptosis. The polymerization of RAD51 is regulated by a number of RAD51 mediators, such as BRCA1, BRCA2, RAD52, SFP1, SWS1, and the five RAD51 paralogs, including XRC3. We here show that brca2-null mutant cells were able to proliferate, indicating that RAD51 can perform DSB repair in the absence of BRCA2. We disrupted the BRCA1, RAD52, SFP1, SWS1, and XRC3 genes in the brca2-null cells. All the resulting double-mutant cells displayed a phenotype that was very similar to that of the brca2-null cells. We suggest that BRCA2 might thus serve as a platform to recruit various RAD51 mediators at the appropriate position at the DNA–damage site.

Citation: Qing Y, Yamazoe M, Hirota K, Dejsuphong D, Sakai W, et al. (2011) The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination. PLoS Genet 7(7): e1002148. doi:10.1371/journal.pgen.1002148

Editor: Michael Lichten, National Cancer Institute, United States of America

Received December 3, 2010; Accepted May 2, 2011; Published July 14, 2011

Copyright: © 2011 Qing et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas and a Grant-in-Aid from the Special Coordination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, and Science of Japan and by grants from The Uehara Memorial Foundation and The Naito Foundation. The funders had no role in study design, data collection and analysis, decision to publish, preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: stakeda@rg.med.kyoto-u.ac.jp

† These authors contributed equally to this work.

Introduction

Homologous recombination (HR) maintains genome integrity by accurately repairing double-strand breaks (DSBs) that arise during the mitotic cell cycle or are induced by radiotherapy [1,2]. HR also plays an important role in releasing the replication forks that stall at damaged template DNA strands [3,4]. Thus, effective HR makes tumor cells tolerant to the chemotherapeutic agents that damage DNA and stall replicative DNA polymerases. Such chemotherapeutic agents include cis-diaminedichloroplatinum(II) (cisplatin), camptothecin, and poly(ADP-ribose) polymerase (PARP) inhibitors, including olaparib (AstraZeneca). Cisplatin is a crosslinking agent that generates intra- and inter-strand cross-links and thereby stalls replicative DNA polymerases. Camptothecin inhibits the ligation of single-strand breaks (SSBs) that are formed during the normal functioning of topoisomerase I. Resulting unrepaird SSBs are converted to DSBs upon replication. Similarly, PARP inhibitors interfere with SSB repair [5]. Since HR plays a major role in repairing DNA lesions generated by camptothecin, cisplatin, and PARP inhibitors [6], measuring HR efficiency in individual malignant tumors may help predict the efficacy of these chemotherapeutic treatment for each tumor [7–9].

HR-dependent DSB repair is accomplished by the following step-wise reactions [10]. DSBs are processed by the Mre11/Rad50/Nbs1 complex and the CtIP, Exo1 and DNA2 nucleases to develop 3′ single-strand DNA (ssDNA) tails [11–17]. RAD51, an essential recombinase, polymerizes on these ssDNAs, leading to the formation of nucleoprotein filaments. These filaments undergo homology search and subsequent invasion into homologous duplex DNA to form a D-loop structure, where they serve as a primer for DNA synthesis [18,19]. After the extended end is displaced from the D-loop, it anneals to its partner-end to complete DSB repair. We know that RAD51 plays a key role in HR in vertebrate cells, as inactivation of RAD51 results in the accumulation of chromosomal breaks in mitotic cells and inhibits the completion of even a single cell cycle [1,2]. The polymerization of RAD51 at damage sites is strictly regulated by a number of accessory factors (hereafter called RAD51 mediators), including the five RAD51 paralogs, SWS1, RAD52, SFP1, BRCA1, BRCA2, and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.

BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats that are conserved in BRCA1 and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.

BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats that are conserved in BRCA1 and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.

BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats that are conserved in BRCA1 and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.

BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats that are conserved in BRCA1 and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.

BRCA2 was originally identified as a tumor suppressor, as germline mutation of the BRCA2 gene results in a high risk of developing breast, ovarian, pancreatic, prostatic, and male breast cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and facilitates the assembly of RAD51 at the single-strand tail. The middle of the BRCA2 protein has eight BRC repeats that are conserved in BRCA1 and PALB2 [3,20–27]. The functional relationships of these RAD51 mediators are poorly understood, because cells deficient in multiple RAD51 mediators have not been established.
Mutations in BRCA1 and BRCA2 predispose hereditary breast and ovarian cancer. Such mutations sensitize to chemotherapeutic agents, including camptothecin, cisplatin, and poly(ADP-ribose) polymerase (PARP) inhibitor, since RAD51 mediators including both BRCA proteins promote repair of DNA lesions induced by these drugs. Little is known of functional relationship among RAD51, BRCA2, and other RAD51 mediators, because no brca2-null cells were available. Furthermore, the phenotype of sws1 null mutants has not been documented. We here disrupted every known RAD51 mediator and analyzed the phenotype of the resulting mutants in both BRCA2-deficient and -proficient backgrounds. The understanding of the function of individual RAD51 mediators and their functional interactions will contribute to the accurate prediction of anti-cancer therapy efficacy.

Results

Loss of SFR1 or SWS1 has a limited impact on DNA-damage responses

To analyze SFR1 and SWS1, we disrupted the sfr1 and sws1 genes in DT40 cells (Figure 1A–1D). Table 1 summarizes the selection marker genes we used to disrupt genes in this study. The resulting sfr1 and sws1 mutant clones proliferated with nearly normal kinetics (Figure 2) and exhibited an increase in cellular sensitivity to cisplatin. The sfr1 mutant was sensitive also to camptothecin and olaparib (Figure 3). Both mutants showed a slight but significant decrease in ionizing-radiation-induced RAD51 focus formation (Figure 4). We conclude that SFR1 and SWS1 indeed work as RAD51 mediators, though their contribution to HR-dependent repair is less significant than that of BRCA1, BRCA2, and the RAD51 paralogs.

The brca2-null mutant is capable of proliferating

To create brca2-null cells, we generated compound heterozygous mutant cells (hereafter called BRCA2–/–/con1 cells) (Figure 1E). The whole coding sequence was deleted in the minus (−) allele of the −/− conditional-null allele-1 (−/−/con1) genotype of the BRCA2−/− cells (Coding sequence deletion allele in Figure 1F). We conditionally deleted the con1 allele of the BRCA2−/− cells by adding tamoxifen, which activated the chimeric Cre recombinase [28] and thereby eliminated the promoter and coding sequences, including exons 1 and 2 of the con1 BRCA2 allelic gene (BRCA2 conditional-null allele-1 in Figure 1F). At day two of continuous tamoxifen treatment, the vast majority of cells lost the intact BRCA2 gene in the conditional allele, and a substantial fraction of cells began to die. To our surprise, we were able to reproducibly establish clonally expanding cells wherein the conditional BRCA2 allele was deleted (BRCA2−/− cells, hereafter called brca2-null cells) from 10 to 20% of the tamoxifen-treated populations. We verified deletion of the BRCA2 allele in the established clones by Southern-blot (Figure 1G) and western-blot (Figure 1H) analysis. The ability of the brca2-deleted cells to proliferate is in marked contrast to the immediate cell death observed in rad51-deleted cells [1]. The plating efficiency of the brca2-null clones was around 20%, which is significantly lower than that of the wild-type (100%) and brca2tr (60%) cells [33].

One obvious concern with this experiment was that expression of the N-terminal-truncated BRCA2 protein in the Cre-mediated deletion lines could allow for residual function. We therefore created a second version of the conditionally inactivated BRCA2 allele, wherein sequences spanning from the promoter to intron 12 could be eliminated by induction of Cre (BRCA2 conditional-null allele-2 in Figure S1). We exposed the resulting compound heterozygous mutant cells to tamoxifen and confirmed reproducible establishment of BRCA2-deleted clones (Text S1). This second brca2 conditional-null allele supported proliferation with generation times very similar to those of the first version of the brca2-null cells (data not shown). The more extensively deleted brca2 clones showed a phenotype indistinguishable from that of the smaller deletion clones, indicating that both deletions confer the null phenotype.

BRCA2 contributes to genome maintenance to a lesser extent than does RAD51

We assessed the proliferative properties of brca2-null clones by monitoring their growth curve (Figure 2A and 2B) and cell cycle (Figure 2C). Wild-type cells doubled every 8 hours and increased in cell number by 64 times over 48 hours. The brca2-null cells increased by 17 times over 48 hours (Figure 2A), calculated as a
Figure 1. Gene disruption of the SFR1, SWS1, and BRCA2 loci. (A) Schematic representation of the endogenous SFR1 locus and gene-disruption constructs carrying the puro or bsr selection marker gene. The solid boxes represent exons, and numbers right above boxes represent exon numbers. Relevant BamHI and EcoRI sites are indicated. (B) Southern-blot analysis of genomic DNA digested by both BamHI and EcoRI was performed using the probe DNA shown in (A). Positions of hybridizing fragments of wild-type (WT) and targeted loci are indicated. (C) Schematic representation of the endogenous SWS1 locus and gene-disruption constructs carrying the puro or his selection marker gene. Relevant EcoRV and NotI sites are indicated. (D) Southern-blot analysis of genomic DNA digested by EcoRV and NotI was performed with the probe DNA shown in (C). (E) Experimental methods to generate BRCA2^{+/c}} cells. We generated BRCA2^{+/c}} cells from conditional mutant BRCA2^{+/c}}/con1 cells. In the minus allele of the BRCA2^{+/c}}/con1 cells, the whole coding sequence is deleted (hereafter called the coding sequence deletion allele). The structures of the conditional-null allele-1 (con1) is shown in (F). Treatment of BRCA2^{+/c}} cells with 4-OH tamoxifen (TAM) led to the generation of BRCA2^{+/c}} cells. (G) Southern-blot analysis of the conditional allele (left) and the other coding sequence deletion (right) allele in BRCA2^{+/c}}/con1 cells with (+) or without (−) TAM treatment. Southern-blot analysis of EcoRI or XbaI-digested genomic DNA was performed with the probe DNA shown in (F). (H) Western-blot analysis to verify the loss of BRCA2 protein in BRCA2^{+/c}} cells derived from BRCA2^{+/c}}/con1 cells. doi:10.1371/journal.pgen.1002148.g001
Figure 2. Decreased cellular proliferation in \textit{brca2-null} cells. (A) Growth curve for cells of the indicated genotype. (B) The relative rate of cell growth per 8 hours (a single cell cycle for wild-type cells) plotted for cells carrying the indicated genotypes. Each value represents the averaged results from three separate experiments. Error bars represent standard deviation. (C) Cell-cycle distribution of \textit{brca2-null} cells that were pulse-labeled with BrdU for 10 minutes and subsequently stained with FITC-conjugated anti-BrdU antibody (Y-axis, log scale) and propidium iodide (PI) (X-axis, linear scale). The upper gate indicates cells incorporating BrdU (S phase), the lower middle gate indicates G1 cells, and the lower-right gate indicates G2/M cells. The sub G1 fraction (lower-left gate) indicates dead cells. The number in each gate indicates the percentage of gated events.

doi:10.1371/journal.pgen.1002148.g002
1.6-fold increase over 8 hours (1.6^8 = 17) (Figure 2B). The number of brca1, brca2ten, and xrc3 clones [36] increased 1.6, 1.9, and 1.8 fold, respectively, over eight hours. The reduced growth kinetics of the brca2-null cells is partly due to apoptosis in a substantial fraction of the cell population, as evidenced by the accumulation of cells in a sub-G1 fraction (Figure 2C).

To understand the cause of this cell death, we measured the number of chromosome breaks in mitotic cells. Forty-six chromosomal aberrations were detectable in 100 mitotic brca2-null cells, larger than the number of aberrations observed in any other RAD51-mediator mutants (Table 2). We therefore conclude that spontaneously arising DSBs resulted in cell death in a fraction of brca2-null cells, thus accounting for the reduced growth kinetics (Figure 2A and 2B). The viability of the brca2-null cells reveals that BRCA2 plays a less important role than does RAD51 in the maintenance of genome integrity [1]. The high number of spontaneously arising chromosomal breaks in the brca2-null cells (Table 2) shows that BRCA2 plays a more fundamental role in genome maintenance than do any of the other RAD51 mediators.

**brca2-null cells displayed a stronger phenotype than the brca1, brca2ten, or rad51 paralog mutant clones**

We analyzed cellular tolerance to camptothecin, cisplatin, and olaparib by measuring cellular survival at 72 hours (7–9 cell cycles) after continuous exposure to these agents in a liquid medium. We did not use the conventional colony-formation assay for this analysis, because the plating efficiency of the brca2-null cells was only 20%, 5-fold lower than that of wild-type cells. Figure 3A presents an example of cellular sensitivity to camptothecin, a DNA-damaging agent. Subsequent figures illustrate the sensitivity of each mutant, assessed by LC50 values, i.e., the dose that reduces cell survival to 50% relative to LC50 value of wild-type cells, which is defined as 100% (Figure 3B–3E).

In the cellular-survival analysis, the brca2-null cells showed an increased sensitivity to camptothecin (Figure 3B), cisplatin (Figure 3C), and olaparib (Figure 3D and 3E). Moreover, sensitivity to cisplatin and olaparib was higher with the brca2-null cells than for any of the other HR mutant cells, including the brca1, rad52, rad54, and xrc3 clones (Figure 3). We therefore conclude that BRCA2 plays a more important role in HR-dependent repair than do the other RAD51 mediators, including BRCA1, RAD52, RAD54, the RAD51 paralogs, SFR1, and SWS1.

The less prominent phenotype of the brca2ten cells compared to the brca2-null cells indicates that the BRCA2 CR3-truncated protein retains significant residual HR function. Although brca1 cells were less sensitive to cisplatin and olaparib than were brca2-null cells, the brca1-null cells exhibited a slightly higher sensitivity to camptothecin than did the brca2-null cells (Figure 3A). The greater contribution of BRCA1 to cellular tolerance to camptothecin might be attributable to the role played by BRCA1 in DNA-damage responses other than HR, such as collaborative action with CtIP to eliminate covalently bound oligo-peptides from DSBs [15].

We next measured the frequency of HR-dependent repair of I-SceI-mediated DSBs in a recombination substrate, SColo, inserted into the OVALBUMIN locus [44,45] (Table 3). The frequency of HR-dependent DSB repair was calculated as the number of neomycin-resistant (neo+) colonies relative to the number of plated cells. The frequency of HR in the brca2-null, brca2ten, and brca1 cells was decreased by 1.5×10^−1, 1.5×10^−2, and 4.5×10^−2-fold, respectively, compared with wild-type cells. We conclude that the brca2-null cells retain residual HR activity, which may account for their viability even in the complete absence of BRCA2.

Since BRCA2 promotes the loading of RAD51 at damage sites, we measured RAD51 focus formation at 3 hours after ionizing radiation. The number of RAD51 foci was reduced but not eliminated in the brca1 and brca2ten clones, compared with wild-type cells (Figure 4). These findings are consistent with previous observations [33,46]. By contrast, we hardly detected any RAD51 focus formation in the brca2-null cells. In conclusion, the BRCA2 protein plays a key role in the efficient recruitment of RAD51 to DNA-damage sites, but is not essential for every HR reaction.

**BRCA2 is required for the effective participation of BRCA1, RAD52, SFR1, SWS1, and XRCC3 in HR**

The idea that RAD51 carries out HR even without BRCA2 led us to investigate whether or not other RAD51 mediators substitute for BRCA2 in the promotion of RAD51-dependent HR. To this end, we deleted the BRCA1, RAD52, SFR1, SWS1, and XRCC3 genes in the conditional brca2-null background, then inactivated the BRCA2 gene by treating the cells with tamoxifen (Figure 1E). We also disrupted the RAD54 gene in the conditional brca2-null background (Table 1). The RAD54 protein promotes HR after the assembly of RAD51 at DNA-damage sites [47]. To our surprise, we were able to reproducibly establish all resulting double mutants, although a substantial fraction (~30%) of the brca2-null cells died each cell cycle.

The growth kinetics for the brca1/brca2-null, rad52/brca2-null, sfr1/brca2, sws1/brca2-null, and xrc3/brca2-null double-mutant clones was similar to that of the brca2-null single mutant (Figure 2). Taking the very severe phenotype of brca1 cells into account, the viability of the brca1/brca2-null cells was surprising. The cloning efficiency of the brca1/brca2-null cells was slightly higher than that of the brca2-null single-mutant cells (30% compared to 20%). Accordingly, the number of spontaneous chromosomal aberrations in the brca1/brca2-null cells was consistently slightly lower than that in the brca2-null cells (Table 2). In summary, although the loss of either BRCA1 or BRCA2 greatly increased the number of spontaneous chromosomal breaks, inactivation of BRCA1 in the brca2-null cells resulted in a slight reduction in the severity of the brca2 phenotype.

An early study shows rad52/xrc3 double-mutant cells are synthetic lethal and exhibit numerous chromosomal breaks [24], whereas we here found that the brca2/brca2 ten and brca2/brca2 double-mutant cells were viable. Thus, the synthetic lethality might be attributable to BRCA2-mediated formation of toxic HR intermediates, because the brca2/xrc3 cells exhibit spontaneously arising isochromatid breaks, where two sisters are broken at the same site due to defective completion of HR [48]. To test this hypothesis, we conditionally inactivated the BRCA2 gene in the rad52/xrc3 cells (Text S1). We found that the inactivation of the BRCA2 gene indeed rescued the rad52/xrc3 cells (Figure S2). This observation indicates that the synthetic lethality of the rad52/xrc3
cells does not argue against the idea that the functioning of RAD52 and XRCC3 depends on BRCA2. Likewise, the formation of toxic HR intermediates might explain the apparent discrepancy between the viability of rad52/brca2-null DT40 cells and the mortality caused by shRNA mediated depletion of RAD52 in brca2 deficient mammalian cells [49], as the latter cells express a residual amount of RAD52 and truncated BRCA2 proteins perhaps leading to the formation of toxic HR intermediates.

We next measured the sensitivity of the brca1/brca2-null, rad52/brca2-null, rad54/brca2-null, sgs1/brca2-null, sws1/brca2-null, and xrc3/brca2-null double-mutant clones to camptothecin, cisplatin, and olaparib (Figure 3 and Figure 5). Remarkably, inactivation of
XRCC3 significantly increased the cellular sensitivity of the HR-dependent repair. By contrast, the loss of RAD52 and absence of BRCA2, SWS1 has a moderately antagonistic effect on focus formation (data not shown). We therefore suggest that, in the absence of BRCA2, SWS1 increased the cellular sensitivity of the brca2-null cells to cisplatin. Similarly, the loss of SWS1 increased the cellular tolerance of the brca2-null cells to camptothecin and olaparib. This increased tolerance was not accompanied by the upregulation of RAD51 focus formation (data not shown). We therefore suggest that, in the absence of BRCA2, SWS1 has a moderately antagonistic effect on HR-dependent repair. By contrast, the loss of RAD52 and XRCC3 significantly increased the cellular sensitivity of the brca2-null cells to olaparib. In summary, BRCA2 is required for all the analyzed RAD51 mediators to function, and the functional relationships between BRCA2 and the other RAD51 mediators in HR-mediated repair differed slightly depending on the type of DNA damage.

Table 1. DT40 mutants used in this study.

| Cell line          | Selection marker for gene disruption | Reference or source |
|--------------------|--------------------------------------|---------------------|
| ssw1               | puro/puro                            | This study          |
| sfr1               | bsr/puro                             | This study          |
| brca2-null         | hyg/his                              | This study          |
| rad52              | bsr/his                              | [69]                |
| rad54              | neo/his                              | [70]                |
| xrcc3              | bsr/his                              | [71]                |
| brca1              | puro/his                             | [46]                |
| brca2tr            | hyg/his                              | [33]                |
| ssw1/brca2-null    | puro/his                             | This study          |
| sfr1/brca2-null    | bsr/puro/his                         | This study          |
| rad52/brca2-null   | hyg/puro/his                         | This study          |
| xrcc3/brca2-null   | hyg/bsr/puro/his                     | This study          |
| rad54/brca2-null   | neo/bsr/puro/his                     | This study          |
| brca1/brca2-null   | hyg/bsr/puro/his                     | This study          |

Table 2. Spontaneous chromosomal aberrations.

| Cell line          | Chromatid-type | Chromosome- | Total |
|--------------------|----------------|-------------|-------|
|                   | Gaps | Breaks | Gaps | Breaks | Exchange | |
| wild-type          | 1    | 1      | 1    | 0      | 0        | 3     |
| xrcc3              | 1    | 1      | 4    | 6      | 0        | 12    |
| rad54              | 1.7  | 0      | 1.7  | 0      | 0.7      | 4.1   |
| brca1              | 6    | 10     | 0    | 6      | 2        | 24    |
| brca2-null         | 16   | 10     | 2    | 18     | 0        | 46    |
| brca2tr            | 4    | 4      | 3    | 3      | 2        | 16    |
| brca1/brca2-null   | 0    | 24     | 3    | 13     | 0        | 39    |

Spontaneous chromosomal aberration of indicated genotypes. Data are the numbers of aberrations per 100 cells. At least 100 mitotic cells were analyzed for each genotype.

doi:10.1371/journal.pgen.1002148.t002

discussion

In this study, we established brca2-null cells as well as cells deficient in each of the RAD51 mediators. We show that BRCA2 plays a more important role in the promotion of both RAD51 polymerization at DNA-damage sites and HR-dependent repair than does any other RAD51 mediator, including BRCA1, the RAD51 paralogs, RAD52, SFR1, and SWS1. The ability of brca2-null cells to proliferate is in marked contrast with the immediate cell death that occurs upon depletion of RAD51 [1]. Therefore, RAD51 is able to perform HR even in the absence of BRCA2. To explore the question of which RAD51 mediators might substitute for BRCA2 in the promotion of RAD51-dependent HR repair, we inactivated the RAD51 mediators in brca2-null cells. Loss of any one of the other RAD51 mediators did not further reduce the viability of brca2-null cells. In a related study, we also found that the brca2-null mutant and the palb2/brca2-null double mutant showed the same phenotype with respect to both spontaneous chromosomal aberrations and increased sensitivity to DNA-damaging agents (manuscript in preparation). Thus we conclude that BRCA1, PALB2, the RAD51 paralogs, RAD52, SFR1, and SWS1 all require BRCA2 to contribute to HR.

BRCA2 plays a major role in the recruitment of RAD51 to DNA-damage sites, but is not essential for every HR reaction.

Data on Ustilago maydis [50] and Arabidopsis thaliana [51] suggest that BRCA2 might be essential for RAD51 to function in any HR reaction. However, we here report that RAD51 can form HR products even in brca2-null cells, indicating that RAD51 plays a more important role than BRCA2 in HR. This hierarchy between RAD51 and BRCA2 is supported by previous reports of experiments with mice, as rad51 null embryos died earlier (~E6.5) than did BRCA2 null (~E8.5) embryos [52,53]. The viability of brca2-null DT40 cells is consistent with the clonal expansion of BRCA2-deficient cells derived from mammary epithelial lineage-specific or T cell lineage-specific BRCA2-null-deficient mice [54,55]. Adding to these findings, we here show solid evidence that vertebrate RAD51 is capable of functioning in the absence of BRCA2.
Table 3. Double strand break-induced gene conversion frequency.

| Cell line            | Relative recombination frequency ± SE | Range of neo<sup>+</sup> colonies per 1×10<sup>7</sup> transfected cells (range) |
|----------------------|---------------------------------------|--------------------------------------------------------------------------------|
| wild-type            | 1.0±0.8                               | 1.1~2.5×10<sup>5</sup>                                                          |
| xrs1                 | 1.3±0.1×10<sup>-1</sup>               | 13~2.0×10<sup>4</sup>                                                           |
| brca1                | 2.2±0.4×10<sup>-1</sup>               | 20~36                                                                          |
| brca2-null           | 6.8±0.9×10<sup>-1</sup>               | 4~11                                                                           |
| brca2tr              | 6.6±4.2×10<sup>-1</sup>               | 347~1493                                                                       |
| srs1/brca2-null      | 7.1±1.5×10<sup>-1</sup>               | 8~15                                                                           |
| sfr1/brca2-null      | 5.6±0.2×10<sup>-1</sup>               | 6~13                                                                           |
| rad52/brca2-null     | 4.4±0.2×10<sup>-1</sup>               | 5~10                                                                           |
| srs3/brca2-null      | 3.0±1.1×10<sup>-1</sup>               | 2~13                                                                           |
| rad54/brca2-null     | 7.6±1.6×10<sup>-1</sup>               | 7~20                                                                           |
| brca1/brca2-null     | 1.9±0.5×10<sup>-1</sup>               | 1~7                                                                            |

Analysis of HR frequency induced by I-SceI-induced DSBs in an artificial substrate. SCneo-puro was stably integrated into the OVALBUMIN locus of indicated genotypes by gene-targeting. 1.0×10<sup>7</sup> cells of each genotype were transfected with 30 μg of either I-SceI expression vector or pBluescript KS, and subsequently selected using a neomycin analog (G418). The ratio of recombination frequency was calculated by comparing the number of G418 resistant clones in the mutant cell lines to that in the wild-type cell line. Only results obtained using the I-SceI expression vector are shown.

doi:10.1371/journal.pgen.1002148.003

Collaboration between BRCA1 and BRCA2 is required for efficient HR

The phenotypic analysis of brca1, brca2-null, and brca1/brca2-null clones, combining with the previous study of rad51-null cells, reveals the functional relationship described as follows. The capability of HR was dramatically diminished when either BRCA1 or BRCA2 was absent, indicating that the collaboration of BRCA2 and BRCA1 is required for efficient HR events. brca2-null cells exhibited more prominent defects in HR than did brca1-null cells, indicating that BRCA2 can function in HR independently of BRCA1. Moreover, BRCA2’s contribution to the repair of cisplatin-induced interstrand crosslinks is more significant than BRCA1, which is likely attributable to the fact that BRCA2, but not BRCA1, functions in the Fanconi anemia repair pathway [56]. BRCA1 has additional functions other than in HR, such as mediating the damage checkpoint and processing DSBs [15,57]. The fact that rad51-null cells have a considerably stronger phenotype than brca1-null cells indicates that RAD51 could still perform HR-dependent repair in brca2-null cells.

The phenotypic similarities between the brca2-null and the brca1/brca2-null clones indicate that BRCA1 contributes to HR by collaborating with BRCA2. Presumably, the two BRCA2 proteins form a functional unit and collaborate intimately to load RAD51 at damage sites. This idea is supported by the fact that BRCA1 physically associates with BRCA2 through the PALB2 protein [58]. However, this idea is challenged by recent studies that suggest that BRCA1 plays a role in the resection of DSBs [14,59]. One possible scenario is that the complex of BRCA1 and BRCA2 may allow for close collaboration between the BRCA1-dependent resection of DSBs and the subsequent loading of RAD51 on the resulting 3’ overhang. Such an interaction interface might be shared by the E. coli RecBCD complex, which serves as the DSB resection complex and also interacts directly with RecA following chi site recognition [60]. In summary, the phenotypic analysis of brca1, brca2-null, and brca1/brca2-null DT40 clones demonstrates that BRCA1 controls RAD51 in HR, mainly through collaboration with BRCA2.

BRCA2 is required for BRCA1, PALB-2, the RAD51 paralogs, SFR1, and SWS1 to promote HR

Our study reveals that rad52/brca2-null, sfr1/brca2-null, sas1/brca2-null, and srs3/brca2-null clones exhibit a phenotype very similar to that of brca2-null cells (Figure 5). In a separate study, we confirmed phenotypic similarity between brca2-null and palb2/brca2-null clones (data not shown). We therefore suggest that, like BRCA1, PALB2, the RAD51 paralogs, RAD5, SFR1, and SWS1 are also able to participate in HR, mostly depending on BRCA2. One possible scenario is that BRCA2 is recruited to DNA-damage sites through PALB2 or by directly interacting with the junction between the duplex DNA and the single-strand sequences [61]. BRCA2 might thus serve as a platform to recruit various RAD51 mediators to the appropriate positions of DNA-damage sites (Figure 6).

Applications for clinical research

DT40 is a unique cell line that offers a panel of DNA-repair-deficient isogenic mutants derived from a stable parental line. DT40 cells have several characteristics that affect cellular responses to anti-cancer agents. First, DT40 appears, for unknown reasons, to possess a significantly higher HR efficiency than any mammalian cell line [43]. The efficient HR in DT40 cells is prominent particularly in HR between diverged homologous sequences such as Immunoglobulin V gene diversification [62] and gene targeting, where the selection marker genes of gene-disruption constructs may interfere with HR as heterologous sequences. Second, like many cancer cells, DT40 lacks the functional p53, and as a result has no G1/S damage checkpoint [63]. In addition, 70% of the DT40 cell cycle takes place in the S phase. Thus, DNA damage at any phase of the cell cycle may have a direct impact on DNA replication. These characteristics, specific to DT40, suggest that a defect in DNA repair associated with DNA replication, including HR-mediated DNA repair, may display a more prominent phenotype in DT40 cells than in other cell lines that have a longer G1 phase and/or a normal G1/S checkpoint. Bearing this in mind, DT40 is revealed as a unique and valuable tool and has been used extensively to explore the role of individual HR factors responsible for cancer therapy.

Materials and Methods

Cell culture and DNA transfection

Cells were acquired and cultured as described previously [1,43]. All mutants were isolated from single colonies. DNA transfection
and selection were performed as described previously [43,64]. Details of the cell lines used in this study are shown in Table 1.

**Generation of SFR1^{−/−} DT40 cells**

To disrupt the SFR1 gene, we generated SFR1-puro and SFR1-bsr disruption constructs by combining two genomic PCR products with the puro- or bsr-selection-marker cassette. Genomic DNA sequences were amplified using the 5′-CCCGGTACTGAGGGGTGCGATTGCTTGCAGG-3′ and 5′-CCCTTAGAGTTGCACTCATTGGCTAAAG-3′ primers for the upstream arm, and the 5′-GGCTCAAACTGGTCAAGATGTACCGATCTAAGG-3′ and 5′-CCACCAGCATCCACTAAAGGGCAAGGA-3′ primers for the downstream arm.

Figure 5. Effect of brca2 deletion on ssw1, sfr1, rad52, rad54, xrc3, and brca1-deficient cells. Cellular sensitivities to the indicated DNA damaging agents were analyzed using the same method as in Figure 3. The LC_{50} values are shown in Figure 3B–3E.

doi:10.1371/journal.pgen.1002148.g005
ACG-3’ primers for the downstream arm. Amplified PCR products were cloned into pCR2.1-TOPO vector (Invitrogen). The 1.7 kb fragment of the upstream arm was cloned into the KpnI site of pCR2.1 containing the 3.0 kb downstream arm. Marker-gene cassettes were inserted at the BamHI site of the resulting plasmid.

To generate SFR1/2 cells, SFR1-puro and SFR1-bsr disruption constructs linearized with NotI were transfected sequentially by electroporation (Bio-Rad). The genomic DNA of the transfectants was digested with both BamHI and EcoRI, and gene-targeting events were confirmed by Southern blot analysis. The probe was prepared from a PCR-amplification of DT40 genomic DNA using primers 5′-GAACAGCACCACGCAATTCA-3’ and 5′-CCTAGAGTTGCACTCATTGG-3’.

Cloning of SFR1 cDNA

Chicken SFR1 cDNA was isolated by PCR amplification of the primary cDNAs using the 5′-GGTTGAGATGGAGGAAGCGCAGGTGTTGTTAAG-3’ and 5′-GACCACTGAAATCCACTTCAAGAG-3’ primers. The gene bank accession number of the chicken SFR1 gene is XM-001234167.

Generation of SWS1/2 DT40 cells

To disrupt the SWS1 gene, we generated SWS1 gene-disruption constructs containing the 2.6 kb upstream and the 3.0 kb downstream genomic fragments. The 2.6 kb fragment was PCR-amplified using the 5′-ggggacaactttgtatagaaaagttgTTCTTACGTCACTCCAGAAGCA-3’ and 5′-ggggactgctttttgtaaacttgC-CAAGTCTGTGAATCGCAGAAGCA-3’ primers. The 3.0 kb fragment was PCR-amplified using the 5′-ggggacagctttcttgtaaaagtggAATTCCAAGCAGTTCCACATCTCT-3’ and 5′-ggggacaactttgtataataaagttgGTATGGCTCTGTCAGGTTAG-3’ primers. Note that the underlined sequences denote the recognition sequences in the Gateway system (Invitrogen). Using the MultiSite Gateway system with pENTR-lox-his, pENTR-lox-puro and pDEST-DTA-MLS [65], a floxed his or puro gene was inserted between the upstream and downstream arms on a plasmid carrying a diphtheria toxin A (DT-A) gene, thus yielding the two targeting vectors, SWS1-his/loxP and SWS1-puro/loxP.

To generate SWS1/2 cells, SWS1-his/loxP and SWS1-puro/loxP gene-disruption constructs linearized with AscI were transfected sequentially into DT40 cells (Bio-Rad). The genomic DNA of the...
transfectants was digested with both EcoRV and NotI, and gene-targeting events were confirmed by Southern-blot analysis. The probe was prepared by PCR-amplification of chicken genomic DNA using the 5'-GCTGGAGGGAACAGACACACTCCITT-3' and 5'-GTACAGGATGTTTCTGCGGG-3' primers.

**Cloning of SWS1 cDNA**

The gene bank accession numbers for the human and chicken Sws1 genes are XP-058899 and XP-415841, respectively. RTPCR of DT40 transcripts was done using the 5'-CAGGGTCCAGA-CATGGATGACCATCCAGC-3' and 5'-CGGGATCCTACTTCCATCTTCCCTC-3' primers.

**Generation of BRCA2-/- DT40 cells**

The brc2-null mutant cells were generated as follows (Figure 1). We inserted conditional brc2 heterozygous cells (BRCA2p/cont) harboring two loxP signals into the other allele upstream of the promoter and downstream of exon 2. Construction of the BRCA2 conditional-null targeting vector was carried out as described previously [33]. To delete the intact allele of the BRCA2p/cont cells, we constructed a targeting vector to delete all exons of the BRCA2 gene. The ~6 kb and ~3.5 kb fragments at the BRCA2 locus [66] were amplified from DT40 genomic DNA by using the 5'-CCGCTGGAGTTTTGTTAAGATGTG-3' and 5'-TTATCAGGGGCTTTGCTACCTTTACT-3' primers and the 5'-CGGGATCCTAATGGTGACATTTCCTG-3' and 5'-GGTGAATTTAACTGGGTAGACAGAG-3' primers, respectively. Both fragments were cloned into TOPO-pCRXL cloning vector (Invitrogen, Carlsbad, California) to make the topo/6.0 kb and topo/3.5 kb vectors. The ~5.2 kb NotI fragment from the topo/6.0 kb vector was inserted into the NotI site in the cloning vector as described previously [66]. To delete the intact allele of the BRCA2p/cont cells, we constructed a targeting vector to delete all exons of the BRCA2 gene. The ~6 kb and ~3.5 kb fragments at the BRCA2 locus [66] were amplified from DT40 genomic DNA by using the 5'-CCGCTGGAGTTTTGTTAAGATGTG-3' and 5'-TTATCAGGGGCTTTGCTACCTTTACT-3' primers and the 5'-CGGGATCCTAATGGTGACATTTCCTG-3' and 5'-GGTGAATTTAACTGGGTAGACAGAG-3' primers, respectively. Both fragments were cloned into TOPO-pCRXL cloning vector (Invitrogen, Carlsbad, California) to make the topo/6.0 kb and topo/3.5 kb vectors. The ~5.2 kb NotI fragment from the topo/6.0 kb vector was inserted into the NotI site in the multicloning site of the topo/3.5 kb vector, resulting in the pUpper/Lower vector. Finally, a loxP-flanked puro-resistance cassette was inserted into the BglII site in the pUpper/Lower vector. The resulting targeting construct was transfected into the BRCA2p/cont cells followed by selection with puromycin. The genomic DNA of the transfectants was digested with XbaI, and gene-targeting events were confirmed by Southern-blot analysis with a probe that was amplified from DT40 genomic DNA by using the 5'-ACATGCTTCCTCCTTC-3' and 5'-GCTCGCAGGAACACAACTCCTT-3' primers. The bands detected by the probe were 8.6 kb from the wild-type allele and 5.2 kb from the targeted allele.

Upon exposure of the BRCA2p/cont cells to tamoxifen, an estrogen antagonist, nucleotide sequences, including promoter and coding sequences encoding the initiation codon to the 67th amino acid, were excised by a chimeric Cre recombinase fused to the estrogen-receptor ligand-binding domain [24], leading to the complete disruption of the BRCA2 gene.

**Disruption of individual HR genes in BRCA2-/- DT40 cells**

To disrupt RAD51 mediator genes in BRCA2-/- DT40 cells, we disrupted each gene in the BRCA2p/cont cells (Table 1). We exposed the resulting RAD51 mediator-/-/BRCA2p/cont cells to tamoxifen and isolated the RAD51 mediator-/-/BRCA2p/cont cells.

**Western blot analysis**

Western blotting was performed as previously described [33]. The rabbit polyclonal primary antibody, which recognizes the N-terminal 203 amino acids of chicken BRCA2, was diluted 1:100 with blocking buffer. The anti-rabbit IgG HRP conjugated antibody was diluted 1:5000 with blocking buffer.

**Flow-cytometric analysis**

To measure flow-cytometric analysis, as described previously [7]. To measure cell-cycle distribution, cells (5 x 10⁶/ml) were labeled for 10 minutes with 20 μmol/L 5-bromo-2’-deoxyuridine (BrdU) and subsequently harvested. Harvested cells were fixed and analyzed as previously described [7].

**Measurement of cellular sensitivity to camptothecin, cisplatin, and olaparib in liquid culture**

To measure cellular survival, (1.5 x 10³–1.5 x 10⁴) were incubated in 1 ml culture medium per well containing various concentrations of the DNA-damaging agents. At 72 hours, the ATP in the cellular lysates was measured to assess the number of live cells. The camptothecin (TopoGen Inc., Columbus, OH) and olaparib (AstraZeneca) were diluted with DMSO, and the cisplatin (Nihonkayaku, Tokyo, Japan) was diluted with PBS. To measure the sensitivity of the DT40 cell lines to these agents, cells were continuously exposed to various concentrations of the drug and the number of cells was measured at 72 hours. At least three independent experiments were carried out. Sensitivity was calculated by dividing the number of cells treated with the drug by the number of untreated cells [6].

**Measurement of ATP to assess cellular sensitivity to DNA damaging agents**

To assess cell numbers after treatment with the genotoxic reagents, we measured the amount of ATP in the whole cell lysate [67].

**Visualization of RAD51 foci**

Cells were harvested at 3 hours after gamma irradiation. Cells were spun onto slides using a Shandon Cytospin 3 centrifuge (Shandon, Pittsburgh, Pa.). Staining and visualization of RAD51 foci were carried out as previously described [34] using rabbit polyclonal antibody, which recognizes human RAD51, at a dilution of 1:500 (Calbiochem, San Diego, CA) and Alexa Fluor 488 goat anti-human IgG antibody at a dilution of 1:1000 (Molecular Probes Inc., Eugene, OR [34]).

**Analysis of chromosomal aberrations**

Measurement of chromosomal aberrations was performed as described previously [68].

**Measurement of HR frequencies for I-Sce1–induced DSB repair**

Measurement of recombination frequencies for I-Sce1–induced DSB repair was performed as described previously [34,44]. Modified Sceneo was inserted into the previously described OVALBUMIN gene construct and targeted into the OVALBUMIN locus in wild-type, xrc3, brc1, brc2, and brc2tr DT40 clones. For transient transfections, 1 x 10⁷ cells were suspended in 0.5 ml of phosphate-buffered saline, mixed with 30 μg of I-Sce1 expression vector (pCBASce) or pBluescript KS without linearization, and electroporated at 250 V, 960 microfarads. At 24 hours after electroporation, the cells were plated in 96-well plates with or without 2.0 mg/ml neomycin analog (G418). The cells were grown for 7 to 10 days, after which formed colonies were counted. HR frequency was calculated by dividing the number of neomycin-resistant colonies by the number of plated cells.

**Statistical analysis**

Survival data were log-transformed giving approximate normality. Analysis of covariance (ANCOVA) was used to test for
Supporting Information

Figure S1 Generation of BRCA2 Δexon2/Δexon2 (ver.2) cells. (A) Experimental methods to generate BRCA2 Δexon2/Δexon2 (ver.2) cells. (B) Schematic representation of the BRCA2 conditional-null allele-2. The conditional-null allele-2 (con2) was generated by targeting the his selection-marker gene flanked by two loxP signals (ploxP-his) in intron 12 of the BRCA2 conditional allele 1. Treatment of the BRCA2 Δexon2/Δexon2 cells causes deletion from the promoter to exon 11, encoding all BRCA motifs. The relevant XhoI sites in the conditional-null allele-1 and the position of the probe used in the Southern-blot analysis are indicated. The solid boxes and arrowheads represent the exons and loxP signals, respectively.

Figure S2 Proliferation and spontaneous chromosomal aberrations of brca2/rad52/xrc3 triple knockout cells. (A) Growth kinetics of the indicated cell cultures in the absence (right) and presence (left) of TAM. Each value represents the averaged results from two separate clones. (B) Cell viability was assessed by flow cytometric analysis of PI uptake and forward scatter (FSC) representing the cell size after tamoxifen (TAM) treatment 4 days. A fixed number of plastic beads was added before flow cytometric analysis to calibrate cell number. Cells falling in the R1 and R2 gates identify dead and viable cells, respectively, and numbers given show their percentages. (C) Spontaneous chromosomal aberrations in cells with indicated genotype after tamoxifen (TAM) treatment 6 days. The data shown in the histogram indicate the types and numbers of chromosomal breaks in 50 analyzed mitotic cells. Two breaks at the same site of both sister chromatids are defined as isochromatid breaks, while breaks at either sister chromatid are chromatid breaks.

Text S1 Supplementary materials and methods.

(Auction)

Acknowledgments

We thank Drs. E. Sonoda and T. Kawamoto for their technical assistance.

Author Contributions

Conceived and designed the experiments: YQ MY KH ST. Performed the experiments: YQ MY KH DD KNY. Analyzed the data: YQ MY KH DKB XW ST. Contributed reagents/materials/analysis tools: YQ MY KH DKB XW ST. Wrote the paper: YQ MY KH ST.
34. Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, et al. (2007) A critical role for the ubiquitin-conjugating enzyme Ubc15 in initiating homologous recombination. Mol Cell 25: 663–675.

35. Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, et al. (2000) The Rad51 paralog Rad51B promotes homologous recombination repair. Mol Cell Biol 20: 6476–6482.

36. Yonetani Y, Hohegger H, Sonoda E, Shinya S, Yoshikawa H, et al. (2005) Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage. Nucleic Acids Res 33: 4544–4552.

37. Murayama Y, Kurokawa Y, Mayanagi K, Iwasaki H (2008) Formation and branch migration of Holliday junctions mediated by eukaryotic recombinases. Nature 451: 1015–1019.

38. Kojic M, Kostrub CF, Buchman AR, Holloman WK (2002) BRCA2 homolog required for proficiency in DNA repair, recombination, and genome stability in Ustilago maydis. Mol Cell Biol 17: 1260–1262.

39. Jensen RB, Carreira A, Kowalczykowski SC (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467: 678–683.

40. Liu J, Doty T, Gibson B, Heyer WD (2010) Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 17: 1260–1262.

41. Buerstedde JM, Takeda S (1991) Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67: 179–188.

42. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, et al. (2011) Rad52 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 64: 3937–3948.

43. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.

44. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.

45. Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263–272.

46. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, et al. (2007) RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67: 9658–9665.

47. Kohzaki M, Nishihara K, Hirota K, Sonoda E, Yoshimura M, et al. (2010) DNA polymerases mu and theta are required for efficient immunoglobulin V gene diversification in chicken. J Cell Biol 189: 1117–1127.

48. Takao N, Kato H, Mori R, Morrison C, Sonoda E, et al. (1999) Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene 18: 7002–7009.

49. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.

50. Bunting SF, Callen E, Wong N, Chen HT, Polato F, et al. (2010) 53BP1 inhibits homologous recombination in BRCA1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.

51. Iwai Y, Takata M, Sasaki MS, Tachiiri S, Fukushima T, et al. (2001) The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 17: 1260–1263.

52. Iiizumi S, Nomura Y, So S, Uegaki K, Aoki K, et al. (2006) Simple one-week mutagenesis of the five Rad51 paralogs. Mol Cell Biol 21: 2858–2866.

53. D’Andrea AD (2010) Susceptibility pathways in Fanconi’s anemia and breast cancer. N Engl J Med 362: 1909–1919.

54. Spies M, Kowalczykowski SC (2006) The RecA binding locus of RecBCD is a general domain for recruitment of DNA strand exchange proteins. Mol Cell 21: 573–580.

55. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, et al. (2001) The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 17: 1260–1263.

56. Kohzaki M, Nishihara K, Hirota K, Sonoda E, Yoshimura M, et al. (2010) DNA polymerases mu and theta are required for efficient immunoglobulin V gene diversification in chicken. J Cell Biol 189: 1117–1127.

57. Takao N, Kato H, Mori R, Morrison C, Sonoda E, et al. (1999) Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene 18: 7002–7009.

58. Yoshimura M, Kohzaki M, Nakamura J, Asagoshi K, Sonoda E, et al. (2006) Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell 24: 115–125.

59. Iizumi S, Nomura Y, So S, Uegaki K, Aoki K, et al. (2006) Simple one-week mutagenesis of the five Rad51 paralogs. Mol Cell Biol 21: 2858–2866.

60. Spies M, Kowalczykowski SC (2006) The RecA binding locus of RecBCD is a general domain for recruitment of DNA strand exchange proteins. Mol Cell 21: 573–580.